 Lauren Fishbein
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pheochromocytoma | 27 | 2025 | 67 | 10.980 |
Why?
| | Paraganglioma | 25 | 2025 | 64 | 9.980 |
Why?
| | Adrenal Gland Neoplasms | 27 | 2025 | 98 | 9.810 |
Why?
| | Neuroendocrine Tumors | 5 | 2024 | 119 | 2.190 |
Why?
| | Succinate Dehydrogenase | 7 | 2025 | 65 | 1.160 |
Why?
| | Biomarkers, Tumor | 4 | 2025 | 1329 | 0.910 |
Why?
| | Mutation | 12 | 2025 | 4090 | 0.840 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2022 | 41 | 0.800 |
Why?
| | Genetic Predisposition to Disease | 7 | 2025 | 2399 | 0.720 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2022 | 58 | 0.680 |
Why?
| | Trans-Activators | 2 | 2021 | 396 | 0.670 |
Why?
| | Meningioma | 1 | 2022 | 88 | 0.650 |
Why?
| | Hospice Care | 1 | 2023 | 228 | 0.610 |
Why?
| | Head and Neck Neoplasms | 4 | 2022 | 561 | 0.600 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 212 | 0.580 |
Why?
| | Adrenocortical Carcinoma | 4 | 2022 | 72 | 0.580 |
Why?
| | Paraganglioma, Extra-Adrenal | 2 | 2022 | 9 | 0.570 |
Why?
| | Chromaffin Cells | 1 | 2018 | 4 | 0.550 |
Why?
| | Genetic Testing | 6 | 2021 | 483 | 0.530 |
Why?
| | Hypertension | 3 | 2022 | 1276 | 0.510 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2024 | 1450 | 0.470 |
Why?
| | Neoplasm Metastasis | 4 | 2025 | 688 | 0.460 |
Why?
| | Genome, Human | 1 | 2018 | 422 | 0.450 |
Why?
| | Adrenal Cortex Neoplasms | 3 | 2022 | 70 | 0.450 |
Why?
| | Disease Management | 2 | 2023 | 653 | 0.430 |
Why?
| | Humans | 46 | 2026 | 145750 | 0.400 |
Why?
| | Exome | 1 | 2015 | 229 | 0.400 |
Why?
| | Germ-Line Mutation | 5 | 2021 | 177 | 0.400 |
Why?
| | DNA Helicases | 1 | 2015 | 136 | 0.390 |
Why?
| | Nuclear Proteins | 2 | 2017 | 740 | 0.390 |
Why?
| | Mutation Rate | 1 | 2013 | 35 | 0.380 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 2 | 2025 | 14 | 0.380 |
Why?
| | Genetic Heterogeneity | 1 | 2012 | 66 | 0.340 |
Why?
| | Thyroid Neoplasms | 2 | 2026 | 370 | 0.340 |
Why?
| | Catecholamines | 3 | 2022 | 88 | 0.330 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 1969 | 0.320 |
Why?
| | Membrane Proteins | 3 | 2021 | 1166 | 0.280 |
Why?
| | Proto-Oncogene Proteins c-ret | 3 | 2025 | 41 | 0.270 |
Why?
| | Neurofibromatosis 1 | 3 | 2019 | 57 | 0.270 |
Why?
| | Middle Aged | 16 | 2025 | 36297 | 0.250 |
Why?
| | Adult | 14 | 2025 | 40867 | 0.240 |
Why?
| | Societies, Medical | 3 | 2021 | 900 | 0.240 |
Why?
| | von Hippel-Lindau Disease | 2 | 2019 | 12 | 0.240 |
Why?
| | Thyroid Diseases | 1 | 2026 | 44 | 0.230 |
Why?
| | Hamartoma Syndrome, Multiple | 1 | 2025 | 16 | 0.230 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2025 | 40 | 0.220 |
Why?
| | Syndrome | 2 | 2019 | 381 | 0.220 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2024 | 12 | 0.210 |
Why?
| | Aged | 10 | 2025 | 26212 | 0.210 |
Why?
| | Drug Therapy | 2 | 2015 | 84 | 0.200 |
Why?
| | Male | 16 | 2025 | 72992 | 0.190 |
Why?
| | Cohort Studies | 5 | 2021 | 6032 | 0.190 |
Why?
| | Retrospective Studies | 9 | 2025 | 17322 | 0.190 |
Why?
| | Cadherins | 1 | 2024 | 200 | 0.190 |
Why?
| | Neoplasm Grading | 2 | 2020 | 311 | 0.180 |
Why?
| | Neoplasms | 1 | 2018 | 2913 | 0.180 |
Why?
| | Dioxygenases | 1 | 2022 | 34 | 0.180 |
Why?
| | Cost of Illness | 1 | 2024 | 324 | 0.170 |
Why?
| | Female | 17 | 2025 | 79025 | 0.170 |
Why?
| | X-linked Nuclear Protein | 2 | 2025 | 8 | 0.170 |
Why?
| | Young Adult | 6 | 2024 | 14250 | 0.170 |
Why?
| | Pennsylvania | 1 | 2020 | 138 | 0.160 |
Why?
| | Otolaryngologists | 1 | 2020 | 13 | 0.160 |
Why?
| | North America | 1 | 2021 | 303 | 0.160 |
Why?
| | Prognosis | 5 | 2022 | 4329 | 0.150 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 498 | 0.150 |
Why?
| | Cyclophosphamide | 2 | 2017 | 272 | 0.150 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 887 | 0.150 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2022 | 258 | 0.150 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 212 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1582 | 0.140 |
Why?
| | Genome-Wide Association Study | 1 | 2026 | 1430 | 0.140 |
Why?
| | Neurofibromin 1 | 2 | 2013 | 26 | 0.140 |
Why?
| | Transcriptome | 2 | 2024 | 1043 | 0.140 |
Why?
| | Adrenal Cortex | 1 | 2018 | 33 | 0.130 |
Why?
| | Medical Oncology | 1 | 2021 | 340 | 0.130 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2018 | 37 | 0.130 |
Why?
| | Cell Proliferation | 3 | 2021 | 2514 | 0.130 |
Why?
| | Electron Transport Complex II | 1 | 2017 | 27 | 0.130 |
Why?
| | Survival Analysis | 1 | 2020 | 1378 | 0.130 |
Why?
| | Pol1 Transcription Initiation Complex Proteins | 1 | 2017 | 5 | 0.130 |
Why?
| | Body Weight | 1 | 2021 | 972 | 0.130 |
Why?
| | Adolescent | 5 | 2024 | 22569 | 0.130 |
Why?
| | Gene Fusion | 1 | 2017 | 30 | 0.130 |
Why?
| | Dacarbazine | 1 | 2017 | 100 | 0.130 |
Why?
| | Endocrinologists | 1 | 2016 | 12 | 0.120 |
Why?
| | Vincristine | 1 | 2017 | 144 | 0.120 |
Why?
| | Apoptosis | 3 | 2021 | 2443 | 0.120 |
Why?
| | Creatine | 1 | 2016 | 63 | 0.120 |
Why?
| | Homologous Recombination | 1 | 2016 | 37 | 0.120 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2016 | 52 | 0.120 |
Why?
| | alpha-Methyltyrosine | 1 | 2015 | 2 | 0.120 |
Why?
| | Mitochondrial Diseases | 1 | 2016 | 92 | 0.120 |
Why?
| | Adrenalectomy | 1 | 2015 | 68 | 0.110 |
Why?
| | Endocrinology | 1 | 2016 | 77 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2020 | 5428 | 0.110 |
Why?
| | Oxidative Phosphorylation | 1 | 2016 | 209 | 0.110 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5921 | 0.110 |
Why?
| | Disease-Free Survival | 1 | 2017 | 770 | 0.110 |
Why?
| | Cardiovascular Diseases | 2 | 2019 | 2190 | 0.110 |
Why?
| | Paclitaxel | 1 | 2016 | 259 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2016 | 534 | 0.110 |
Why?
| | Telomere Homeostasis | 1 | 2015 | 33 | 0.110 |
Why?
| | Radiotherapy | 1 | 2015 | 206 | 0.110 |
Why?
| | Palliative Care | 1 | 2023 | 1022 | 0.110 |
Why?
| | Research Design | 1 | 2020 | 1139 | 0.100 |
Why?
| | Tumor Burden | 1 | 2015 | 325 | 0.100 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2015 | 108 | 0.100 |
Why?
| | 3-Iodobenzylguanidine | 1 | 2013 | 13 | 0.100 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2013 | 19 | 0.100 |
Why?
| | Enzyme Inhibitors | 2 | 2015 | 821 | 0.100 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 24 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 447 | 0.090 |
Why?
| | Thoracic Neoplasms | 1 | 2013 | 39 | 0.090 |
Why?
| | Abdominal Neoplasms | 1 | 2013 | 47 | 0.090 |
Why?
| | Genetic Variation | 1 | 2018 | 976 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 1101 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 440 | 0.090 |
Why?
| | Multiple Endocrine Neoplasia | 1 | 2012 | 5 | 0.090 |
Why?
| | Pancreatic Neoplasms | 1 | 2020 | 928 | 0.090 |
Why?
| | Telomere | 1 | 2015 | 287 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 6084 | 0.080 |
Why?
| | Prospective Studies | 1 | 2023 | 8075 | 0.080 |
Why?
| | Quality of Life | 1 | 2023 | 3210 | 0.080 |
Why?
| | Chromatin | 1 | 2015 | 553 | 0.080 |
Why?
| | Schwann Cells | 1 | 2010 | 33 | 0.080 |
Why?
| | Mass Screening | 1 | 2019 | 1361 | 0.080 |
Why?
| | Models, Biological | 1 | 2018 | 1764 | 0.080 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 595 | 0.080 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2013 | 431 | 0.080 |
Why?
| | Gene Expression | 1 | 2015 | 1478 | 0.080 |
Why?
| | Comprehension | 1 | 2012 | 186 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 2 | 2025 | 322 | 0.070 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 1482 | 0.070 |
Why?
| | Child | 5 | 2022 | 22738 | 0.070 |
Why?
| | Progesterone | 1 | 2010 | 215 | 0.070 |
Why?
| | Transcription Factors | 1 | 2017 | 1736 | 0.070 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1474 | 0.070 |
Why?
| | Aged, 80 and over | 2 | 2021 | 8346 | 0.070 |
Why?
| | Estrogens | 1 | 2010 | 367 | 0.070 |
Why?
| | Signal Transduction | 1 | 2021 | 5223 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2010 | 936 | 0.060 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1777 | 0.060 |
Why?
| | Referral and Consultation | 1 | 2013 | 868 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2016 | 1791 | 0.060 |
Why?
| | Blood Pressure | 1 | 2013 | 1782 | 0.060 |
Why?
| | DNA Modification Methylases | 1 | 2025 | 18 | 0.060 |
Why?
| | DNA Repair Enzymes | 1 | 2025 | 29 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 2219 | 0.050 |
Why?
| | United Kingdom | 1 | 2025 | 358 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 1 | 2025 | 165 | 0.050 |
Why?
| | Risk Factors | 2 | 2021 | 10916 | 0.050 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 3551 | 0.050 |
Why?
| | Phenylglyoxal | 1 | 2022 | 2 | 0.050 |
Why?
| | Telomerase | 1 | 2025 | 246 | 0.050 |
Why?
| | Pituitary Neoplasms | 1 | 2024 | 190 | 0.050 |
Why?
| | Succinates | 1 | 2022 | 25 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2022 | 116 | 0.040 |
Why?
| | Succinic Acid | 1 | 2022 | 46 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2022 | 118 | 0.040 |
Why?
| | Antigens, CD | 1 | 2024 | 558 | 0.040 |
Why?
| | United States | 3 | 2025 | 16122 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2002 | 335 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 343 | 0.040 |
Why?
| | Urinary Bladder | 1 | 2022 | 196 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 228 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 337 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2022 | 337 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2021 | 238 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2021 | 371 | 0.040 |
Why?
| | Lamin Type B | 1 | 2018 | 6 | 0.040 |
Why?
| | NIMA-Related Kinases | 1 | 2018 | 9 | 0.030 |
Why?
| | DNA Methylation | 1 | 2023 | 690 | 0.030 |
Why?
| | Naphthyridines | 1 | 2018 | 20 | 0.030 |
Why?
| | Prevalence | 1 | 2025 | 2874 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 478 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2026 | 2181 | 0.030 |
Why?
| | Histones | 1 | 2023 | 666 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 735 | 0.030 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 35 | 0.030 |
Why?
| | Aldosterone | 1 | 2018 | 42 | 0.030 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 53 | 0.030 |
Why?
| | Immunoblotting | 1 | 2018 | 295 | 0.030 |
Why?
| | Oncogenes | 1 | 2018 | 118 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 337 | 0.030 |
Why?
| | Animals | 3 | 2022 | 38100 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2022 | 3915 | 0.030 |
Why?
| | Gene Frequency | 1 | 2018 | 489 | 0.030 |
Why?
| | Phosphocreatine | 1 | 2016 | 44 | 0.030 |
Why?
| | Platinum Compounds | 1 | 2016 | 10 | 0.030 |
Why?
| | Genomics | 1 | 2021 | 831 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 188 | 0.030 |
Why?
| | Mitochondria, Muscle | 1 | 2016 | 120 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2016 | 427 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 625 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2025 | 2770 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 630 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1723 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 971 | 0.030 |
Why?
| | Exercise Test | 1 | 2016 | 630 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 778 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1247 | 0.020 |
Why?
| | Computational Biology | 1 | 2018 | 669 | 0.020 |
Why?
| | Preoperative Care | 1 | 2015 | 380 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2016 | 534 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1708 | 0.020 |
Why?
| | Phenotype | 1 | 2020 | 3170 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2010 | 118 | 0.020 |
Why?
| | Drug Implants | 1 | 2010 | 83 | 0.020 |
Why?
| | Hemodynamics | 1 | 2015 | 1118 | 0.020 |
Why?
| | Algorithms | 1 | 2018 | 1850 | 0.020 |
Why?
| | Ovariectomy | 1 | 2010 | 166 | 0.020 |
Why?
| | Mice | 2 | 2022 | 18357 | 0.020 |
Why?
| | Mice, SCID | 1 | 2010 | 369 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 3118 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2010 | 3130 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2002 | 410 | 0.010 |
Why?
| | Pedigree | 1 | 2002 | 515 | 0.010 |
Why?
| | Exons | 1 | 2002 | 364 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 11793 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 5992 | 0.010 |
Why?
| | Infant | 1 | 2010 | 10089 | 0.010 |
Why?
| | Child, Preschool | 1 | 2010 | 11866 | 0.010 |
Why?
|
|
Fishbein's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|